Abstract
Associated with a significant disease burden and symptom experience, advanced gastric cancer is incurable . This international randomised controlled trial studied the effect of the addition of trastuzumab to chemotherapy for patients with human epidermal growth factor receptor-2 positive advanced gastric or gastro-oesophageal junction cancer, versus chemotherapy alone. Quality of life was assessed using two internationally validated self-administered questionnaires, the European Organisation for Research and Treatment of Cancer QLQ-C30 and the gastric cancer specific QLQ-STO22. The addition of the monoclonal antibody prolonged time to deterioration and increased quality-adjusted survival, without seemingly altering general toxicity burden or compromising quality of life. Satoh T, Bang Y, Gotovkin E et al (2014) Quality of life in the trastuzumab for gastric cancer trial. The Oncologist. 19, 7, 712-719.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
